Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs

Cancer Letters

Volumn 266, Issue 2, 2008, Pages 249-262

  Cao, Cong ^a,b   Lu, Shan ^a   Sowa, Alex ^a   Kivlin, Rebecca ^a   Amaral, Ashley ^a   Chu, Wenming ^b   Yang, Hui ^c   Di, Wen ^c   Wan, Yinsheng ^a  

^a PROVIDENCE COLLEGE   (United States)

^b BROWN UNIVERSITY   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Down regulation; EGF; EGFR inhibitor; Ovarian cancer; Tyrosine kinase

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CBL PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG RESPONSE; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MITOGENESIS; OVARY CANCER; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; MICE; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 45049084213     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.062     Document Type: Article

References (41)

1. Chan J.K., Pham H., You X.J., Cloven N.G., Burger R.A., Rose G.S., Van Nostrand K., Korc M., Disaia P.J., and Fan H. Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res. 65 (2005) 3243-3248
2. Berchuck A., Rodriguez G.C., Kamel A., Dodge R.K., Soper J.T., Clarke-Pearson D.L., and Bast Jr. R.C. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. 164 (1991) 669-674
3. Maihle N.J., Baron A.T., Barrette B.A., Boardman C.H., Christensen T.A., Cora E.M., Faupel-Badger J.M., Greenwood T., Juneja S.C., Lafky J.M., Lee H., Reiter J.L., and Podratz K.C. EGF/ErbB receptor family in ovarian cancer. Cancer Treat. Res. 107 (2002) 247-258
4. Morishige K., Kurachi H., Amemiya K., Fujita Y., Yamamoto T., Miyake A., and Tanizawa O. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 51 (1991) 5322-5328
5. Ottensmeier C., Swanson L., Strobel T., Druker B., Niloff J., and Cannistra S.A. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br. J. Cancer 74 (1996) 446-452
6. Moriai T., Kobrin M.S., Hope C., Speck L., and Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. USA 91 (1994) 10217-10221
7. Hackel P.O., Zwick E., Prenzel N., and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11 (1999) 184-189
8. Albanell J., and Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 6 (2005) 259-274
9. Honegger A.M., Dull T.J., Felder S., Van Obberghen E., Bellot F., Szapary D., Schmidt A., Ullrich A., and Schlessinger J. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51 (1987) 199-209
10. Eldredge E.R., Korf G.M., Christensen T.A., Connolly D.C., Getz M.J., and Maihle N.J. Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor. Mol. Cell Biol. 14 (1994) 7527-7534
11. Matsuda K., Idezawa T., You X.J., Kothari N.H., Fan H., and Korc M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res. 62 (2002) 5611-5617
12. Sweeney C., and Carraway III K.L. Negative regulation of ErbB family receptor tyrosine kinases. Br. J. Cancer 90 (2004) 289-293
13. Stang E., Blystad F.D., Kazazic M., Bertelsen V., Brodahl T., Raiborg C., Stenmark H., and Madshus I.H. Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol. Biol. Cell 15 (2004) 3591-3604
14. Aguilar R.C., and Wendland B. Endocytosis of membrane receptors: two pathways are better than one. Proc. Natl. Acad. Sci. USA 102 (2005) 2679-2680
15. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., Lavi S., Iwai K., Reiss Y., Ciechanover A., Lipkowitz S., and Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4 (1999) 1029-1040
16. Jiang X., Huang F., Marusyk A., and Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell 14 (2003) 858-870
17. Waterman H., Katz M., Rubin C., Shtiegman K., Lavi S., Elson A., Jovin T., and Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 21 (2002) 303-313
18. Qiu L., Wang Q., Di W., Jiang Q., Schefeller E., Derby S., Wanebo H., Yan B., and Wan Y. Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int. J. Oncol. 27 (2005) 823-830
19. Qiu L., Di W., Jiang Q., Scheffler E., Derby S., Yang J., Kouttab N., Wanebo H., Yan B., and Wan Y. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int. J. Oncol. 27 (2005) 1441-1448
20. Cao C., Healey S., Amaral A., Lee-Couture A., Wan S., Kouttab N., Chu W., and Wan Y. ATP-sensitive potassium channel: a novel target for protection against UV-induced human skin cell damage. J. Cell Physiol. 212 (2007) 252-263
21. Cao C., Sun Y., Healey S., Bi Z., Hu G., Wan S., Kouttab N., Chu W., and Wan Y. EGFR-mediated expression of aquaporin-3 is involved in human skin fibroblast migration. Biochem. J. 400 (2006) 225-234
22. Dragoi A.M., Fu X., Ivanov S., Zhang P., Sheng L., Wu D., Li G.C., and Chu W.M. DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. Embo. J. 24 (2005) 779-789
23. Ravid T., Heidinger J.M., Gee P., Khan E.M., and Goldkorn T. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J. Biol. Chem. 279 (2004) 37153-37162
24. Han W., Zhang T., Yu H., Foulke J.G., and Tang C.K. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol. Ther. 5 (2006) 1361-1368
25. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., and Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 5 (2003) 461-466
26. Clague M.J., and Urbe S. Endocytosis: the DUB version. Trends Cell Biol. 16 (2006) 551-559
27. Grovdal L.M., Stang E., Sorkin A., and Madshus I.H. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp. Cell Res. 300 (2004) 388-395
28. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., Sela M., and Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 102 (2005) 1915-1920
29. Blank S.V., Chang R., and Muggia F. Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology 19 (2005) 553-559
30. Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., Di Fiore P.P., and Polo S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 102 (2005) 2760-2765
31. He Y.Y., Huang J.L., Gentry J.B., and Chignell C.F. Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity. J. Biol. Chem. 278 (2003) 42457-42465
32. Khan E.M., Heidinger J.M., Levy M., Lisanti M.P., Ravid T., and Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J. Biol. Chem. 281 (2006) 14486-14493
33. Yamabhai M., and Anderson R.G. Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts. J. Biol. Chem. 277 (2002) 24843-24846
34. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99 (2002) 157-166
35. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. Faseb. J. 13 (1999) 781-792
36. Liotta L.A., Steeg P.S., and Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64 (1991) 327-336
37. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89 (1997) 1260-1270
38. Ling X., Bernacki R.J., Brattain M.G., and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J. Biol. Chem. 279 (2004) 15196-15203
39. Kamb A. Cell-cycle regulators and cancer. Trends Genet. 11 (1995) 136-140
40. Sherr C.J. D-type cyclins. Trends Biochem. Sci. 20 (1995) 187-190
41. Strauss M., Lukas J., and Bartek J. Unrestricted cell cycling and cancer. Nat. Med. 1 (1995) 1245-1246